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Ruel and Suuronendoi:10.1016/j.jtcvs.2005.01.013Objective: Off-pump coronary artery bypass grafting may result in fewer myocardial
and vascular complications than on-pump. Although differences in aortic manipu-
lations likely play a role, the systemic responses of endothelial progenitor cells to
both types of operations have not been examined. We sought to examine endothelial
progenitor cell characteristics after off-pump versus on-pump coronary artery by-
pass grafting.
Methods: Twenty patients undergoing off-pump or on-pump coronary artery bypass
grafting were prospectively enrolled and had endothelial progenitor cells isolated
and cultured from their peripheral blood before and 24 hours after surgery. Endo-
thelial progenitor cells were identified by fluorescent dual lectin/low-density li-
poprotein binding. Their number, phenotype characteristics, proliferation, migratory
function, and viability were determined in a blinded fashion.
Results: Patient characteristics and numbers of grafts were equivalent. Endothelial
progenitor cells had similar phenotypes between groups before and after surgery.
Off-pump and on-pump coronary artery bypass grafting resulted in similar increases
in endothelial progenitor cell numbers and showed equivalent proliferation activity.
However, endothelial progenitor cell migratory function was higher in off-pump
patients (25.3  5.0 vs 5.0  1.0 cells per high-powered field for off-pump vs
on-pump coronary artery bypass grafting, respectively; P  .04). Postoperative
endothelial progenitor cell viability adjusted for preoperative baseline was also
higher after off-pump than on-pump coronary artery bypass grafting by 72.4% 
14.6% (P  .01). Endothelial progenitor cells of on-pump patients were less viable
after surgery than before surgery, whereas the reverse was observed in off-pump
patients.
Conclusions: Both on-pump and off-pump coronary artery bypass grafting elicit
mobilization of endothelial progenitor cells into the peripheral blood. On-pump
coronary artery bypass grafting, however, impairs the migratory function and
viability of these vascular repair cells, which are conversely preserved after off-
pump surgery. Further work is necessary to determine whether the function and
viability of endothelial progenitor cells correlate with vascular outcomes and
whether their therapeutic modulation may one day benefit coronary artery bypass
grafting patients.
Endothelial progenitor cells (EPCs) are a subtype of circulating bonemarrow– derived cells that have the potential to proliferate and differen-tiate into mature endothelial cells at virtually any site in the body.1,2
Recent work has indicated that these processes continue to occur in adults and
play a role not only in the prevention of endothelial dysfunction and cardiovas-
cular disease progression,3 but also in the response to inflammation, cardiac
The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 3 633
Cardiopulmonary Support and Physiology Ruel et al
CSPischemia, myocardial infarction, and other vascular
insults.4-6 EPCs accelerate re-endothelialization and re-
duce vascular inflammation after vascular injury,7 and an
impaired function of these cells has been correlated with
adverse vascular events such as in-stent restenosis and
poor collateral development in adults.8,9
Vascular trauma, such as trauma that occurs during cor-
onary artery bypass grafting (CABG), leads to a cascade of
events that result in vasomotor dysfunction and chemoat-
traction of leukocytes to cardiac and extracardiac sites.
Off-pump coronary artery bypass (OPCAB) has been asso-
ciated with fewer perioperative vascular complications—
including renal dysfunction, stroke, and myocardial infarc-
tion—than conventional on-pump CABG,10-13 and this may
relate in part to less aortic manipulation.14 However, the
comparative effects of on-pump CABG versus OPCAB on
circulating EPCs remain unknown. Their elucidation may
help us to better understand the vascular responses to these
2 types of coronary bypass operations and explain some of
the differences observed in myocardial and vascular out-
comes. In this study, we examined and compared in a
prospective setting the number, phenotype, proliferation
activity, migratory function, and viability of EPCs in on-
pump CABG and OPCAB patients before and after
surgery.
Methods
Patients, Blood Samples, and Surgical Procedures
The study was approved by the Human Research Ethics Board of
the University of Ottawa Heart Institute, and informed consent was
obtained from all patients. Low-risk patients (n  20; 10 per
group) who had stable, angiographically documented 2- or 3-
vessel coronary artery disease and who were scheduled to undergo
primary on-pump CABG or OPCAB without another concomitant
cardiac surgical procedure were eligible for the study. Exclusion
criteria were emergency status, known ascending aortic disease,
type 1 diabetes, chronic renal failure, current smoking, cancer,
anticoagulation with warfarin, coagulopathy, liver dysfunction,
immunomodulating agents such as steroids or other immunosup-
pressants, administration of granulocyte colony-stimulating factor,
recent or active infection, and implantation of an intra-aortic
balloon pump or ventricular assist device. All patients received
general anesthesia with a routine protocol; on-pump CABG (but
not OPCAB) patients also received low-dose intravenous tranex-
amic acid according to a standardized protocol.
The cell-characterization procedures involved the harvest of 30
mL of fresh blood from a central venous catheter placed in the left
jugular vein after anesthetic induction immediately before surgery.
Twenty-four hours after surgery, another 30 mL of blood was
taken from the same central venous catheter. EPCs were isolated,
cultured, positively identified, and counted; their phenotype was
examined; and their function was evaluated with proliferation,
migration, and viability assays as described below.
The surgical procedures within each study group were per-
formed by the same 2 surgeons, each with a CABG caseload that
involved the use of beating-heart revascularization for approxi-
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versus OPCAB in each patient was not dictated by protocol and
had been determined for all patients before entry into the study.
On-pump operations were performed with standard heparin man-
agement and by using cold crystalloid cardioplegia. OPCAB op-
erations used a heparin dose of 150 U/kg intravenously, adjusted to
reach a target activated clotting time of 300 seconds during the
grafting period, and were performed by using an apical suction
device and epicardial coronary stabilizer (Medtronic, Toronto,
Canada). After surgery, on-pump and OPCAB patients received
650 mg of acetylsalicylic acid within 6 hours of operation.
Cell Isolation and Culture
Total peripheral blood mononuclear cells (MNCs) were isolated
from fresh blood samples by Histopaque 1077 (Sigma-Aldrich,
Oakville, Canada) density-gradient centrifugation of buffy coats.
One million MNCs per square centimeter were plated on fibronectin-
coated tissue culture flasks and cultured in endothelial basal me-
dium (EBM-2; Clonetics, Guelph, Canada) supplemented with
EGM-2-MV-SingleQuots (Clonetics) containing 5% fetal bovine
serum, 50 ng/mL human vascular endothelial growth factor
(VEGF), 50 ng/mL human insulin-like growth factor 1, and 50
ng/mL human epidermal growth factor. After 4 days in culture,
nonadherent cells were removed by washing, new medium was
applied, and the culture was maintained through day 4. To confirm
the EPC phenotype, direct fluorescent staining was used to detect
dual binding of fluorescein isothiocyanate (FITC)-labeled Ulex
europaeus agglutinin 1 (ulex-lectin; Sigma, Oakville, Canada) and
1,1=-dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine (DiI)-
labeled acetylated low-density lipoprotein (acLDL; Molecular
Probes, Burlington, Canada) on attached adherent cells in day 4
culture. Cells were visualized with a fluorescent microscope, and
adherent cells that stained positive for both FITC–ulex-lectin and
DiI-acLDL were considered to be EPCs.15 Ten randomly selected
high-powered fields (HPFs) from 2 individual wells were exam-
ined in each sample, and the number of dual-staining cells was
counted by an observer blinded to the patient’s study group.
Flow Cytometry
To examine the EPC phenotype, detached cells were examined by
flow cytometry. Cells were labeled for 20 minutes at manufacturer-
recommended concentrations with the following fluorescent anti-
bodies: anti-CD34 (a stem/progenitor cell marker detected on
cultured EPCs), anti–vascular endothelial (VE) cadherin (an en-
dothelial lineage marker), and anti–VEGF receptor 2 (VEGF-R2;
also an endothelial lineage marker). Samples were analyzed in a
blinded fashion by using a Beckman-Coulter flow cytometer
(Beckman, Mississauga, Canada).
Functional Assays
To examine the proliferation potential and function of cultured
EPCs, proliferation, migration, and viability assays were per-
formed on cells after 7 days (proliferation and migration) and 4
days (viability) of culture by using the conditions described pre-
viously. Previous reports have demonstrated maintenance after in
vitro incubation of the phenotypic differences of EPCs at the time
of harvest.16-20
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PProliferation. For the proliferation assay, 7-day-cultured EPCs
were lifted by pipetting vigorously, replated onto 96-well plates
precoated with fibronectin, and serum-depleted for 24 hours. After 24
hours, EPCs were supplemented with 10 L methyl-thiazol-diphenyl-
tetrazolium (5 g/L; Sigma) and incubated for another 4 hours. The
supernatant was discarded by aspiration, the EPC preparation was
shaken with 200 L of dimethyl sulfoxide for 10 minutes, and the
solution’s optical density was measured at 490 nm.
Migration. For determination of cell migration, isolated cells
were detached by vigorous pipetting, harvested by centrifugation,
resuspended in 500 L of EBM-2 with supplements, and counted.
Then, 2  104 EPCs were placed in the upper chamber of a
modified Boyden chamber (Hemogenix, Colorado Springs, Colo)
while VEGF (10 ng) in serum-free media was placed in the lower
chamber. After 24 hours of incubation at 37°C, cells were stained
for quantification with the fluorescent dye carboxifluorescein di-
acetate. Cells that migrated into the lower chamber were counted
manually in 3 random HPFs by a blinded observer. As a negative
control, EPC migration was also compared with that of healthy
volunteers (n  3).
Viability. Cell viability was determined with the trypan blue
exclusion method. When cells die, their membrane becomes perme-
able and allows uptake of the trypan blue dye, and nonviable/dead
cells become darker than the viable cells. To determine nonviability,
fresh blood EPCs and EPCs cultured for 4 days in a 35-mm fibronec-
tin-coated dish were detached with phosphate-buffered saline with 1
mmol/L ethylenediaminetetraacetic acid, followed by gentle shifting,
and were resuspended after centrifugation in a total volume of 2.0 mL
per dish. Nonviable cells were counted from starting random samples
of 3  106 cells in triplicate in an automated fashion by using a
Vi-Cell Beckman-Coulter counter (Beckman).
Statistical Analysis
Values are expressed as mean  standard error of the mean.
Statistical analyses were performed in Intercooled Stata 8
(Stata, College Station, Tex). Mean postoperative-preoperative
EPC nonviability ratios were calculated for each patient as
follows: postoperative-preoperative EPC nonviability ratio 
(postoperative percentage of nonviable cells  preoperative
percentage of nonviable cells)/preoperative percentage of non-
viable cells  100%. Comparisons of continuous data between
groups were performed with analysis of variance. Dichotomous
variables were compared within groups by using the Fisher
exact test.
Results
Patient Characteristics and Outcomes
Table 1 displays the characteristics of the patients enrolled
in the study. There were no crossovers or intraoperative
conversions between the on-pump CABG and OPCAB
groups, and there were no significant differences in preop-
erative characteristics, the number of grafts, or the incidence
of postoperative complications. Mean cardiopulmonary by-
pass and aortic crossclamp times in on-pump patients were
69.7  5.5 minutes and 45.5  4.8 minutes, respectively.
All patients were free from readmission or major adverse
cardiac events at the 1-month follow-up.
The Journal of ThoraciCell Numbers and Phenotype
After 4 days in culture, MNCs isolated from the patients’
blood that exhibited a spindle-shaped endothelial cell–like
morphology, adherence, and positive staining for both DiI-
acLDL uptake and lectin binding were characterized as
EPCs (Figure 1). At 24 hours after surgery, on-pump CABG
and OPCAB resulted in an increase in the number of cir-
culating EPCs of 54.3%  32.2% and 44.1%  17.2%,
respectively, compared with the preoperative baseline (P 
.88 between the on-pump and OPCAB groups). Flow cy-
tometry analysis revealed that EPCs of on-pump CABG
versus OPCAB patients had similar phenotypes before and
after surgery, with no significant difference in the expres-
sion of CD34, VE cadherin, or VEGF-R2 at any study time
point between the on-pump and OPCAB patients. Overall,
CD34, VE cadherin, and VEGF-R2 markers were expressed
in 45.4%  3.8%, 95.0%  1.2%, and 90.2%  3.0% of
cells, respectively.
Proliferation
There was no difference in postoperative proliferation ac-
tivity between EPCs harvested from on-pump CABG versus
OPCAB patients. Proliferation activity measured by light
absorbance at 490 nm was 0.154  .015 versus 0.157 
.008 in the on-pump versus the OPCAB group, respectively
(P  .9).
Migration
Boyden chamber assays revealed increased postoperative
TABLE 1. Patient characteristics and operative variables
Variable
On-pump CABG
(n  10)
OPCAB
(n  10)
Female sex 1 1
Age, y (mean  SEM) 58.3  2.7 63.3  4.3
Body surface area (m2) 2.0  0.1 1.8  0.1
Left ventricular ejection
fraction 40%
2 2
Hypertension 5 4
Type 2 diabetes 0 2
Preoperative serum
creatinine, mol/L
(mean  SEM)
101.7  15.8 107.5  15.9
No. grafts (mean  SEM) 2.5  0.2 2.5  0.2
Blood transfusion 3 3
Reopening for bleeding 0 0
Myocardial infarction,
stroke, or death
0 0
Hospital length of stay, d
(mean  SEM)
6.2  1.7 4.9  0.6
CABG, Coronary artery bypass grafting; OPCAB, off-pump CABG; SEM,
standard error of the mean.EPC migration in OPCAB patients versus on-pump CABG
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CSPpatients (Figure 2); migration was 25.3  5.0 cells per HPF
in OPCAB patients, versus 5.0  1.0 cells per HPF in
on-pump CABG patients (P  .04). the EPC migratory
activity of OPCAB patients was also higher than that of
healthy volunteers, who exhibited a cell migration capacity
of 16.0  6.1 cells per HPF, but the difference was not
statistically significant (P  .05).
Viability
Details of viability analyses are presented in Figure 3.
Before surgery, there was no significant difference in EPC
nonviability between the on-pump CABG and OPCAB
groups (9.7%  1.0% vs 12.3%  2.0% of nonviable cells
before surgery for the on-pump and OPCAB groups, respec-
tively; P  .2). However, 24 hours after surgery, the num-
ber of dead/nonviable EPCs had increased to 13.4% 1.0%
in the on-pump CABG group, whereas the number of non-
viable cells had decreased to 8.4%  0.4% in the OPCAB
group (P  .001 vs the on-pump CABG group). Further-
more, the mean of individual postoperative-preoperative
EPC nonviability ratios was58.7% 22.3% for on-pump
CABG patients; in contrast, OPCAB patients demon-
strated a negative (13.8%  14.6%) mean postoperative-
preoperative EPC nonviability ratio (P  .02 vs the on-
pump group). Overall, the mean cumulative difference in
Figure 1. Endothelial progenitor cells 24 hours after surgery (orig-
inal magnification, 400). Mononuclear cells isolated from the
peripheral blood (in this example, from an OPCAB patient) were
characterized as endothelial progenitor cells if they exhibited
spindle-shape endothelial cell–like morphology and stained dou-
ble-positive for lectin binding (green) and labeled acetylated
low-density lipoprotein (red).postoperative-preoperative EPC nonviability ratios between
636 The Journal of Thoracic and Cardiovascular Surgery ● Septthe on-pump and OPCAB groups was 72.4%  17.7%, in
favor of the OPCAB group.
Discussion
Main Findings
The main findings of this study were that (1) CABG per-
formed on cardiopulmonary bypass, although it results in an
increased number of postoperative EPCs, in accordance
with previous work,21,22 significantly impairs the migratory
capacity and viability of EPCs after surgery, as evidenced
by significant differences found in EPCs harvested from
on-pump CABG patients 24 hours after surgery. These
changes were significant not only compared with a matched
control OPCAB group population, but also, in the case of
viability assays, compared with preoperative baseline, ie,
using each on-pump CABG patient as his or her own
control. In addition, the data from this study indicate that (2)
OPCAB, like on-pump CABG, increases circulating EPC
numbers after surgery and that (3) OPCAB, in contrast to
on-pump CABG, preserves the viability and migratory
function of EPCs after surgery.
Clinical Implications
The implications of these findings are potentially multiple
Figure 2. Migration assays of cultured human EPCs (original
magnification, 100). Photomicrographs of day 7 cultured EPCs
harvested 24 hours after surgery from on-pump CABG and OPCAB
patients. There was improved EPC migration in samples from the
OPCAB compared with the on-pump patients (P  .04; see text).
Also shown are day 7 cultured EPCs harvested from a healthy
volunteer who did not undergo operation. The postoperative EPC
migratory activity of OPCAB patients was also higher than that of
healthy volunteers, but this difference was not statistically sig-
nificant (P  .05; see text).yet speculative at present. In a growing body of evidence
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Psuggesting that EPCs play a role in preventing vascular
events and abnormal vascular healing, this study provides
the first available data on the functional response of EPCs to
on-pump CABG, as well as the first comparison of these
responses to those encountered after OPCAB. These find-
ings suggest that the different functional responses of EPCs
may constitute an additional biological basis, in addition to
known mechanical and surface-related factors, such as aor-
tic cannulation, clamping, and platelet/leukocyte activation,
in explaining the higher rate of multisystemic vascular
complications with on-pump CABG versus OPCAB re-
ported in the literature.10-13 In this regard, a notable dis-
crepancy exists between reports of a trend or a significantly
lower incidence of perioperative myocardial infarction with
OPCAB versus on-pump CABG in systematic reviews to
date,10,12,13 despite findings of lower angiographic graft
patency with OPCAB in 2 of 3 large randomized controlled
trials.23-25 This study was not, however, powered to verify
whether EPC functional responses account for this discrep-
ancy nor to verify whether a correlation exists between
clinical vascular events and postoperative EPC function
between and within on-pump CABG and OPCAB patient
groups. It was also not designed to determine for how long
the differences persist in EPC viability and function be-
tween on-pump CABG and CABG herein identified at 24
hours after surgery. The present findings nevertheless pro-
vide a rationale for future work to elucidate these ques-
tions; this could, in turn, subsequently justify investigat-
ing the role of EPC-modulating agents such as granulocyte
macrophage-colony growth factor18 in decreasing myocar-
dial and extracardiac vascular complications after on-pump
CABG and possibly other cardiac operations that involve
cardiopulmonary bypass.
Possible Mechanistic Correlates
Migration. The EPCs cultured from OPCAB patients
demonstrated an improved ability to migrate compared with
those obtained from on-pump CABG patients. No differ-
ences in EPC expression of VE cadherin (an adhesion
protein) or VEGF-R2 were, however, observed between
OPCAB and CABG patients, and it therefore seems un-
likely that these would have contributed to the observed
difference in migratory potential. Among other candidates
are integrins (including 1 and 2), which are involved in
EPC adhesion and migration26 and whose integrin-linked
kinase and subsequent survival kinase Akt activity promotes
endothelial cell migration, survival, and cardiac repair.27
Another family of proteins involved in the regulation of
migration through the extracellular environment are the
matrix metalloproteinases (MMPs), which are proteases se-
creted by migrating cells. Upregulation of MMP-9 expres-
sion is required for the recruitment of EPCs from the bone
marrow from their quiescent to their activated state.28 How-
The Journal of Thoraciever, the effects of MMPs on the characteristics of EPCs
and on determining their migratory potential are currently
unknown and represent, like that of integrin expression, a
new focus for investigation.
Viability. There was a significant difference in the via-
bility of EPCs from CABG and OPCAB patients. Although
equipped with antioxidative stress-associated genes, EPCs
can be affected by oxidative stress, with an associated
increase in apoptosis.29 Because OPCAB is associated with
less oxidative stress than on-pump CABG,30 it is possible
that the enhanced viability of EPCs in OPCAB patients is
related to this mechanism.
Limitations
Controversy exists as to what truly constitutes a circulating
EPC, because cell types reported as EPCs in the literature
vary greatly. Although most investigators use dual binding
of FITC–ulex-lectin and DiI-acLDL, as well as phenotype
characteristics of endothelial cells, to define EPCs,15 pluri-
potent blood monocytes may actually constitute 1 of 2 types
of so-called EPCs described in the human peripheral blood.2
The functional difference between the 2 EPC populations,
Figure 3. Endothelial progenitor cell (EPC) nonviability after on-
pump CABG versus OPCAB. On-pump CABG and OPCAB had no
significant difference in EPC viability before surgery. However,
postoperative viability, the absolute increase in nonviability, and
the mean postoperative-preoperative EPC nonviability ratio were
significantly higher in patients who underwent on-pump CABG
than in those who underwent OPCAB.which may be distinguished by their proliferating potential
c and Cardiovascular Surgery ● Volume 130, Number 3 637
Cardiopulmonary Support and Physiology Ruel et al
CSPand viability after 4 to 6 weeks in in vitro culture, is unclear
because both cell types seem to play a role in neovascular-
ization and re-endothelialization and have the ability to
differentiate into endothelial cells.
The study was not randomized, and although preopera-
tive patient characteristics and intraoperative data were bal-
anced between the 2 groups, it remains possible that un-
known confounders affected the results. The number of
patients did not allow for a multivariate determination of
other potential risk factors for EPC nonviability/dysfunc-
tion, such as age or diabetes mellitus, which were respec-
tively lower and less prevalent, albeit not significantly, in
the on-pump CABG versus the OPCAB group. These small
differences, equally unlikely to be have been avoided in a
randomized study of similar size, may nevertheless have
resulted in the apparent yet nonsignificant difference in
preoperative EPC nonviability between the on-pump CABG
and OPCAB groups. To minimize the effect of these poten-
tial biologic imbalances, all analyses of EPC number and
viability in this study were adjusted with respect to preop-
erative baseline, and assessments of EPC migratory func-
tion were compared with those of healthy volunteers.
Conclusions
Despite these limitations, this study provides new insight
into the biological responses to on-pump CABG, which
results in decreased EPC migratory function and EPC via-
bility, as well as to OPCAB, which does not lead to either
of these effects. Although the implications of these findings
are still incompletely understood, previous work that has
linked EPCs with the prevention of vascular events and the
promotion of normal vascular healing suggests that these
responses could play a role in the pathogenesis of a higher
rate of vascular complications after on-pump CABG com-
pared with OPCAB. These data also provide a rationale for
future work examining whether EPC responses after cardiac
operations correlate with vascular events and healing and
the subsequent investigation of the possible role of thera-
peutic interventions that could modify the response of EPCs
after cardiac surgery.
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